PMID- 30302873
OWN - NLM
STAT- MEDLINE
DCOM- 20200306
LR  - 20200306
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 40
IP  - 11
DP  - 2018 Nov
TI  - Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic 
      head and neck cancer treated with cetuximab.
PG  - 2424-2431
LID - 10.1002/hed.25353 [doi]
AB  - BACKGROUND: Cetuximab combined with chemoradiotherapy chemotherapy is the 
      standard therapy for recurrent/metastatic head and neck squamous cell carcinoma 
      (HNSCC). However, survival benefit is limited. The purpose of this study was to 
      investigate the expression of epiregulin (EREG) and amphiregulin (AREG), as 
      predictive prognostic markers for the efficacy of cetuximab combined with 
      chemotherapy in R/M HNSCC. METHODS: We conducted a retrospective analysis of 37 
      patients diagnosed with R/M HNSCC. Tumor samples were analyzed for EREG and AREG 
      mRNA gene expression, and clinical outcomes evaluated. RESULTS: Values of EREG 
      and AREG were associated with significantly longer overall survival (OS) (P = .03 
      and P = .01, respectively), as well as progression-free survival (PFS) (P = .04 
      and P = .04, respectively). Multivariate analysis revealed that AREG expression 
      was significantly associated with OS and PFS. CONCLUSIONS: Patients with 
      recurrent/metastatic HNSCC with higher EREG and AREG gene expression appear to 
      benefit more from cetuximab combined with chemoradiotherapy chemotherapy than 
      those with lower expression.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Kogashiwa, Yasunao
AU  - Kogashiwa Y
AUID- ORCID: 0000-0003-1074-2326
AD  - Department of Head and Neck Surgery, Otolaryngology, Saitama Medical University 
      International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
FAU - Inoue, Hitoshi
AU  - Inoue H
AD  - Department of Head and Neck Surgery, Otolaryngology, Saitama Medical University 
      International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
FAU - Kuba, Kiyomi
AU  - Kuba K
AD  - Department of Head and Neck Surgery, Otolaryngology, Saitama Medical University 
      International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
FAU - Araki, Ryuichiro
AU  - Araki R
AD  - Community Health Science Center, Saitama Medical University, 38 Morohongo, 
      Moroyama, Iruma-gun, Saitama, 350-0495, Japan.
FAU - Yasuda, Masanori
AU  - Yasuda M
AD  - Department of Pathology, Saitama Medical University International Medical Center, 
      1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
FAU - Nakahira, Mitsuhiko
AU  - Nakahira M
AD  - Department of Head and Neck Surgery, Otolaryngology, Saitama Medical University 
      International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
FAU - Sugasawa, Masashi
AU  - Sugasawa M
AD  - Department of Head and Neck Surgery, Otolaryngology, Saitama Medical University 
      International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181010
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - 0 (Amphiregulin)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Epiregulin)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amphiregulin/*genetics
MH  - Analysis of Variance
MH  - Biomarkers, Tumor/analysis
MH  - Cetuximab/*therapeutic use
MH  - Chemoradiotherapy/methods
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Disease-Free Survival
MH  - Epiregulin/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Head and Neck Neoplasms/drug therapy/*genetics/mortality/pathology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/drug therapy/*genetics/mortality/pathology
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/drug 
      therapy/*genetics/mortality/pathology
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - AREG
OT  - EREG
OT  - EGFR
OT  - biomarker
OT  - cetuximab
EDAT- 2018/10/12 06:00
MHDA- 2020/03/07 06:00
CRDT- 2018/10/11 06:00
PHST- 2017/11/25 00:00 [received]
PHST- 2018/02/12 00:00 [revised]
PHST- 2018/05/16 00:00 [accepted]
PHST- 2018/10/12 06:00 [pubmed]
PHST- 2020/03/07 06:00 [medline]
PHST- 2018/10/11 06:00 [entrez]
AID - 10.1002/hed.25353 [doi]
PST - ppublish
SO  - Head Neck. 2018 Nov;40(11):2424-2431. doi: 10.1002/hed.25353. Epub 2018 Oct 10.